Tumor physiology and drug resistance

Cancer and Metastasis Reviews

Volumn 20, Issue 1-2, 2001, Pages 123-132

  Tannock, Ian F ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Drug resistance; Microenvironment; Repopulation; Tissue penetration

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; METHOTREXATE; VERAPAMIL; VINBLASTINE;

ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CELL HYPOXIA; DRUG ACCUMULATION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT FAILURE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0035689646     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013125027697     Document Type: Article

References (52)

1. Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
2. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-azacytidine-induced demethylation of the hMLH1 promoter
3. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour
4. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor
5. Tumour cell proliferation in relation to the vasculature
6. Response of Chinese Hamster ovary cells to anti-cancer drugs under aerobic and hypoxic conditions
7. Role of hypoxia in anticancer drug-induced cytotoxicity for Ehrlich ascites cells
8. Acid pH in tumors and its potential for therapeutic exploitation
9. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan
10. Factors that influence the penetration of methotrexate through solid tissue
11. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation
12. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
13. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors
14. Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents
15. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer
16. Quinidine as a resistance modulator of Epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
17. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Study Group Study
18. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor
19. Endothelial cell proliferation in experimental tumours
20. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
21. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
22. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
23. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
24. Resistance to Adriamycin in multicellular spheroids
25. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy
26. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids
27. Doxorubicin distribution in multicellular prostate cancer spheroids evaluated by confocal laser scanning microscopy and the 'optical probe technique'
28. Doxorubicin gradients in human breast cancer
29. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342
30. Chemosensitivity testing in V79 spheroids: Drug delivery and cellular micro-environment
31. Distribution and activity of antineoplastic drugs in a tumor model
32. Slow penetration of anthracyclines into spheroids and tumors: A therapeutic advantage?
33. Multicellular membranes as an in vitro model for extravascular diffusion in tumours
34. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours
35. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
36. Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors
37. Measurement of delivery and metabolism of tiripazamine to tumor tissue using the multilayered cell culture model
38. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers
39. Defective acidification in human breast tumor cells and implications for chemotherapy
40. The hazard of accelerated tumor clonogen repopulation during radiotherapy
41. Tumour cell repopulation during fractionated radiotherapy: Correlation between flow cytometric and radiobiological data in three murine tumours
42. Clinical evidence for tumor clonogen regeneration: Interpretations of the data
43. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx
44. The effect of treatment duration in the local control of cervix cancer
45. CHART (continuous, hyperfractionated, accelerated radiotherapy): A tale of two disciplines
46. Repopulation of tumour cells between cycles of chemotherapy: A neglected factor
47. In vivo clonogenioc tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy
48. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3 cyclohexyl-l-nitrosourea
49. Dynamics of tumor clonogen repopulation in a murine sarcoma treated with cyclophosphamide
50. Tumor resistance to therapy: A genetic or kinetic problem?
51. Rapid tumor cell proliferation after induction chemotherapy in oropharngeal cancer
52. Tumor size, sensitivity to therapy, and design of treatment schedules